Analysis of efficacy of sorafenib combined with vascular endothelial growth factor inhibitor on renal cell carcinoma.
To investigate the short-term efficacy of sorafenib combined with vascular endothelial growth factor (VEGF) inhibitor in the treatment of renal cell carcinoma (RCC). A total of 64 patients with RCC were randomly divided into the control group (n=32) and the observation group (n=32). Patients in the control group were treated with sorafenib tosylate tablets alone, while those in the observation group were treated with Avastin based on the treatment in the control group. The changes in the levels of peripheral T lymphocyte subset, natural killer (NK) and VEGF, changes in the quality of life (QoL), short-term efficacy and major clinical adverse reactions were compared between the two groups before and after treatment. The levels of cluster of differentiation CD3+, CD4+, CD4+/CD8+ and NK and the QoL score in the observation group after treatment were significantly increased compared with those before treatment and in the control group, while the level of CD8+ was significantly lower than that before treatment and in the control group (p<0.05). The level of VEGF in the observation group at 2 and 3 months after treatment was lower than that before treatment and in the control group (p<0.05). In the observation group, the effective control rate and 3-year survival rate were remarkably higher than those in the control group (p<0.05). Moreover, there was no statistically significant difference in the incidence rate of clinical adverse reactions between the two groups (p>0.05). Sorafenib combined with Avastin can significantly improve the immune function, reduce the expression level of VEGF, improve the QoL, prolong the survival and obtain satisfactory short-term efficacy in RCC patients, which has important application value in the clinical treatment of RCC.